摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1'S,2'R,7'R,9'S,11'S,12'S,16'S,18'S)-2',16'-dimethyl-18'-phenyldispiro[1,3-dioxolane-2,5'-[8]oxapentacyclo[9.7.0.02,7.07,9.012,16]octadecane-15',2''-[1,3]dioxolane]-18'-ol | 1422160-55-1

中文名称
——
中文别名
——
英文名称
(1'S,2'R,7'R,9'S,11'S,12'S,16'S,18'S)-2',16'-dimethyl-18'-phenyldispiro[1,3-dioxolane-2,5'-[8]oxapentacyclo[9.7.0.02,7.07,9.012,16]octadecane-15',2''-[1,3]dioxolane]-18'-ol
英文别名
——
(1'S,2'R,7'R,9'S,11'S,12'S,16'S,18'S)-2',16'-dimethyl-18'-phenyldispiro[1,3-dioxolane-2,5'-[8]oxapentacyclo[9.7.0.02,7.07,9.012,16]octadecane-15',2''-[1,3]dioxolane]-18'-ol化学式
CAS
1422160-55-1
化学式
C29H38O6
mdl
——
分子量
482.617
InChiKey
IRJHPHFFPHMHIX-PYEWTQAYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    35
  • 可旋转键数:
    1
  • 环数:
    8.0
  • sp3杂化的碳原子比例:
    0.79
  • 拓扑面积:
    69.7
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    (1'S,2'R,10'S,11'S,15'S,17'S)-2',15'-Dimethyl-17'-phenyldispiro[1,3-dioxolane-2,5'-tetracyclo[8.7.0.02,7.011,15]heptadecane-14',2''-[1,3]dioxolan]-7'-en-17'-ol间氯过氧苯甲酸 作用下, 以77%的产率得到(1'S,2'R,7'R,9'S,11'S,12'S,16'S,18'S)-2',16'-dimethyl-18'-phenyldispiro[1,3-dioxolane-2,5'-[8]oxapentacyclo[9.7.0.02,7.07,9.012,16]octadecane-15',2''-[1,3]dioxolane]-18'-ol
    参考文献:
    名称:
    A ring-distortion strategy to construct stereochemically complex and structurally diverse compounds from natural products
    摘要:
    高通量筛选是药物发现过程中确定先导化合物的主要方法。因此,筛选库的组成在很大程度上决定了可调节的生物靶点和可开发的治疗方法。遗憾的是,大多数化合物筛选库主要由结构或立体化学复杂性较低的平面分子组成,这些化合物无法提供调节许多药物靶点所需的化学功能排列。在这里,我们介绍了一种新颖、通用和简便的策略,即利用现成的天然产物作为合成起点,创造出具有高结构和立体化学复杂性的多种化合物。我们通过对化学性质(包括 sp3 碳的比例、ClogP 和立体中心的数量)的评估表明,这些化合物的复杂性和多样性明显高于标准筛选集合中的化合物。本文介绍了一种构建复杂多样化合物库的方法,即通过一系列环系统畸变反应改变天然产物。生成的化合物与标准筛选库中的化合物具有明显不同的理化性质,因此在寻找可开发成候选药物的先导分子方面具有优势。
    DOI:
    10.1038/nchem.1549
点击查看最新优质反应信息

文献信息

  • COMPLEX AND STRUCTURALLY DIVERSE COMPOUNDS
    申请人:The Board of Trustees of the University of Illinois
    公开号:US20150274638A1
    公开(公告)日:2015-10-01
    The invention provides a novel, general, and facile strategy for the creation of small molecules with high structural and stereochemical complexity. Aspects of the methods include ring system distortion reactions that are systematically applied to rapidly convert readily available natural products to structurally complex compounds with diverse molecular architectures. Through evaluation of chemical properties including fraction of sp 3 carbons, ClogP, and the number of stereogenic centers, these compounds are shown to be significantly more complex and diverse than those in standard screening collections. This approach is demonstrated with natural products (gibberellic acid, adrenosterone, and quinine) from three different structural classes, and methods are described for the application of this strategy to any suitable natural product.
    这项发明提供了一种新颖、通用且简便的策略,用于创造具有高结构和立体化学复杂性的小分子。该方法的方面包括系统地应用于快速将易得的天然产物转化为具有多样分子结构的结构复杂化合物的环系统失真反应。通过评估化学性质,包括sp3碳的分数、ClogP和立体中心的数量,这些化合物被证明比标准筛选集合中的化合物显着更复杂和多样化。这种方法是通过来自三个不同结构类别的天然产物赤霉酸肾上腺酮奎宁)来展示的,并描述了将该策略应用于任何合适的天然产物的方法。
  • Complex and structurally diverse compounds
    申请人:The Board of Trustees of the University of Illinois
    公开号:US10800730B2
    公开(公告)日:2020-10-13
    The invention provides a novel, general, and facile strategy for the creation of small molecules with high structural and stereochemical complexity. Aspects of the methods include ring system distortion reactions that are systematically applied to rapidly convert readily available natural products to structurally complex compounds with diverse molecular architectures. Through evaluation of chemical properties including fraction of sp3 carbons, ClogP, and the number of stereogenic centers, these compounds are shown to be significantly more complex and diverse than those in standard screening collections. This approach is demonstrated with natural products (gibberellic acid, adrenosterone, and quinine) from three different structural classes, and methods are described for the application of this strategy to any suitable natural product.
    本发明提供了一种新颖、通用和简便的策略,用于制造具有高结构和立体化学复杂性的小分子。该方法的各个方面包括系统地应用环系畸变反应,将容易获得的天然产物快速转化为具有不同分子结构的结构复杂的化合物。通过对化学特性(包括 sp3 碳的比例、ClogP 和立体中心的数量)进行评估,这些化合物的复杂性和多样性明显高于标准筛选集合中的化合物。该方法通过三种不同结构类别的天然产物赤霉素肾上腺甾酮奎宁)进行了演示,并介绍了将该策略应用于任何合适的天然产物的方法。
  • [EN] COMPLEX AND STRUCTURALLY DIVERSE COMPOUNDS<br/>[FR] COMPOSÉS COMPLEXES ET DE STRUCTURES DIVERSES
    申请人:HERGENROTHER PAUL J
    公开号:WO2013142873A2
    公开(公告)日:2013-09-26
    The invention provides a novel, general, and facile strategy for the creation of small molecules with high structural and stereochemical complexity. Aspects of the methods include ring system distortion reactions that are systematically applied to rapidly convert readily available natural products to structurally complex compounds with diverse molecular architectures. Through evaluation of chemical properties including fraction of sp3 carbons, ClogP, and the number of stereogenic centers, these compounds are shown to be significantly more complex and diverse than those in standard screening collections. This approach is demonstrated with natural products (gibberellic acid, adrenosterone, and quinine) from three different structural classes, and methods are described for the application of this strategy to any suitable natural product.
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)